Claudio Albrecht, co-founder and managing partner of
Albrecht, Prock & Partners was until August 31st, 2018 CEO
of the publicly listed STADA AG. Before this assignment
Claudio worked in and with the Generic industry for more than
30 years.
Claudio started his pharmaceutical career at Sandoz in 1987 in
Austria and became General Manager of its generic businesses
in the Netherlands, in Germany and the USA, before leaving to
become CEO of the Ratiopharm Group in 2000. In his time as CEO
of the Ratiopharm Group he was driving the
internationalization process of the German drug maker beyond
Europe and was material for the initiation of the development,
manufacturing and commercialization project of Ratiopharm’s
Biosimilars program. Ratiopharm was first to market with the
Biosimilar Filgrastim in Europe.
In 2007 Claudio founded together with Peter Prock the strategy
consulting firm CoMeth in Slovakia before he was asked to
assume the role of CEO and Chairman of the Board of the
Actavis Group. Actavis was operating in over 50 countries
worldwide with standalone 2012 revenues in excess of €
2billion. Under his leadership, Actavis was sold to Watson for
6 bio US$, which represented an above average industry
multiple. As CEO of Actavis Claudio initiated a total turn
around process and started a joint venture for the development
and commercialization of recombinant Insulin and its Analogues
with the objective to build the first Generic “one stop shop”
in Diabetes.
After the divestiture of Actavis, Claudio founded with Peter
Prock the Zug/Switzerland based Albrecht, Prock & Partners
AG. Together with Private Equity and strategic investors
AP&P worked on numerous acquisition projects amongst which
the take private initiative for STADA AG was the most
significant. STADA AG was the largest leveraged buyout of a
German listed company ever. Claudio agreed to manage the
company for an interim period of one year and led all the
necessary changes and strategic initiatives. In September 2018
Claudio returned to AP&P. Claudio holds a PhD in law.
Peter Prock, co-founder and managing partner of Albrecht, Prock & Partners was, until 2012 the Deputy CEO of the Actavis Group and as such a decisive player in the turn around and divestiture of the company. Peter started his pharmaceutical career at Sandoz and worked in several positions in Austria, Spain, USA and Germany before leaving to become the CFO of the Ratiopharm Group , before its acquisition by Teva. After the divestiture of Actavis Peter founded together with Claudio AP&P and took on many project assignments in the Generic industry amongst others he also acted for 2 years as interim-CEO for Polpharma and serves on the board of several Pharmaceutical companies. Peter holds a Masters degree in Business Administration.
Wolter Kuizinga, partner of Albrecht, Prock & Partners, served as member of the Board of the Actavis Group in the capacity of Executive Vice-President Business Development. Wolter started his career in Solvay in 1987, being responsible for contracting out sterile manufacturing. After four years he joined Ciba-Geigy to define and build Ciba’s European generics portfolio. After the merger with Sandoz, Wolter co-founded Disphar International, a leading European generics development and out-licensing company, where he was responsible for the company’s Portfolio Management, Business Development and Legal Affairs. Wolter holds a Pharmacist’s degree from the University of Utrecht (NL) and an MBA from the University of Bradford (UK).
Jeff Rope served as Global Head of Technical Operations for Sandoz and a member of the Sandoz Executive Committee. Jeff was responsible for a network of more than 30 manufacturing sites and external supply organisations supplying more than 160 countries worldwide. Jeff has over 35 years experience in Pharmaceutical Operations. Previously Jeff was Executive VP Global Operations for Actavis and has held Plant leadership roles in Pfizer Global Manufacturing. Jeff has a NZCS in Chemistry from Auckland Technical University, a Diploma in Analytical Chemistry from the Royal Society of Chemistry, an Executive MBA from University College Cork and is currently undertaking an MSC in Personal and Organisational coaching at UCC.
Sean Bowler, partner of Albrecht, Prock & Partners, is an engineer who has been Head of Global Engineering and HSE in two major pharmaceutical companies. Sean started his career in API manufacturing, and worked in a number of positions of increasing responsibility in the industry. With extensive global operational, engineering and HSE experience. He has successfully developed and managed corporate systems in areas such as capital management, project and program delivery, asset life cycle management, network optimisation, people development in technical roles and safety performance. Sean has a track record in delivering projects globally, and has successfully managed project portfolios of up to $750M in value. Sean is a Chemical Engineer, with an MBA. He is currently completing a research doctorate with Cranfield University, UK, on the determinants of performance in global production networks.
Markus is a partner at Albrecht Prock & Partners and was formerly VP for Comp &/ Ben for Actavis Group where Markus was instrumental in designing, implementing and controlling various Compensation and Benefits projects and initiatives. He was also responsible for the global HR budget, developing and introducing of various HR strategies, pooling of insurances and leading DD teams in various COC situations.
Prior to his engagement with Actavis, Markus served as CFO for various Healthcare companies and Fast moving Consumer goods companies.
Markus is a certified public accountant and graduated as an MBA from GSBA Zuerich / SUNY New York.
Petar Bast, Partner at Albrecht, Prock & Partners, until recently served as Vice-President Business Intelligence at Allergan (previously Actavis). After Allergan Petar founded a Swiss consulting and pharma company with a group of ex-Actavis colleagues.
Petar started his career in Copenhagen in 1995, developing manufacturing plants for Ferring and Lundbeck. Later he worked for Amgen in various commercial/ marketing roles in the UK and Switzerland. Before joining Actavis, Petar built up the Business Analysis function at Vifor Pharma. Petar holds an MBA from London Business School, an M.Sc. (Pharm.Med.) from Essen University, a B.Com. (Org. Development) from Copenhagen Business School and an M.Sc. (Pharm. Eng.) from the Technical university of Denmark
Born and educated in Berlin, Stephan
Walz holds a degree from free university of Berlin
both in Chemistry and Pharmacy. In 1990, he started
his professional career in the pharmaceutical industry
at Schering AG (today Bayer) in the galenic
department. Later on, he was Head of Business
Development and production at Heinz Haupt for 8 years
to join afterwards Lindopharm as Head of Production,
Development and Managing Director. In 2008, he founded
Aristo Pharma together with the former Hexal founders.
Until 2015 Stephan was the CEO of Aristo, a
Germany-headquartered, multi-country pharmaceutical
company. During Stephan’s 14 years at the helm of
Aristo the company grew significantly, both
organically and through a series of acquisitions, to
become one of Germany’s leading generics and OTC
pharma companies.
Following the acquisitions of Invent Farma and Neuraxpharm in 2016 by funds advised by Apax Partners, Stephan Walz was appointed Chief Executive Officer. He assumed the newly-created role of Group CEO and he built an international specialty pharma company with a footprint in 9 European countries.